ABBV vs. ILMN: AbbVie vs. Illumina Stock Comparison

Company Profile

AbbVie (ABBV) and Illumina (ILMN) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while ILMN is classified in Life Sciences Tools & Services.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Illumina (ILMN) has an aggressive beta of 1.46, indicating higher sensitivity to broad-market moves, while AbbVie (ABBV) is defensive at 0.21 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Illumina (ILMN) earns 32.39% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

Illumina (ILMN) at 19.72% keeps the most of each sales dollar — above its industry’s net margin range — and AbbVie (ABBV) at 15.67% also retains a top-quartile share.

Both AbbVie (ABBV) at 39.59% and Illumina (ILMN) at 20.02% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

AbbVie (ABBV) at 8.57% is around its peer norm for revenue growth, while Illumina (ILMN) at -0.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: AbbVie (ABBV) reports EPS growth of -0.84%, ranked against its industry; Illumina (ILMN) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Illumina (ILMN) at 2.63 keeps current ratio within its industry’s typical mid-range, while AbbVie (ABBV) at 0.87 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ABBV.

Only one side’s leverage can be read here: Illumina (ILMN) carries debt-to-equity ratio of 0.74 against its industry range, while AbbVie (ABBV) reports no figure this period.

Financial Strength Metrics

Dividends

Illumina (ILMN) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; Illumina (ILMN) pays no dividend (payout 0.00%).

Dividend Metrics

Valuation

Illumina (ILMN) at 36.68 is near its industry’s usual P/E ratio, while AbbVie (ABBV) at 50.05 sits in the richer quartile — ABBV needs stronger growth or earnings quality to justify the premium.

On P/S ratio, both AbbVie (ABBV) at 7.80 and Illumina (ILMN) at 7.10 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Illumina (ILMN) reports 10.30, ranking against industry peers normally.

Valuation Metrics